Market Performance
Acrux Limited (ASX: ACR) closed its most recent trading session with a 10 % rally, reaching AUD 0.01 per share at 02:43 PM Central European Time on Friday, 23 November 2026. The stock’s liquidity remains modest, with a current supply of 410.6 million shares and a market capitalisation of AUD 6.1 million. In the past 24 hours, the exchange volume amounted to approximately AUD 538,142, underscoring a healthy, albeit thin, trading base.
Since the close of last month’s trading week, Acrux has appreciated 15.79 %, a gain that aligns closely with the 200‑day simple moving average, also positioned at AUD 0.01. The company’s all‑time high of AUD 0.02 was logged on 28 May 2026, while the 52‑week low of AUD 0.01 was recorded on 30 September 2026, indicating a relatively narrow trading band.
Governance and Capital‑Raising Agenda
Acrux has announced its Annual General Meeting (AGM) for 24 November 2026, scheduled for 10:00 a.m. AEDT in Melbourne. Shareholders will review four ordinary resolutions:
- Re‑election of Ross Dobinson as a director.
- Issue of rights to non‑executive directors as part of their remuneration package.
- Adoption of the remuneration report covering the 2026 fiscal year.
- Special resolution approving a 10 % placement capacity for equity securities.
The AGM will also present the company’s audited financial statements for the year ended 30 June 2026, providing a comprehensive view of its recent performance and future outlook. Shareholders are encouraged to cast their votes or appoint a proxy via instructions available on the company’s website, ensuring robust participation in these pivotal governance matters.
Peer Activity Snapshot
| Stock | 24‑Hour Change | Current Price | Market Cap | Notes |
|---|---|---|---|---|
| H2G (H2G.AX) | 0 % | AUD 0.01 | AUD 7.2 M | Flat |
| TRM (TRM.AX) | +2.08 % | AUD 0.05 | AUD 7.3 M | Modest gain |
| EM2 (EM2.AX) | 0 % | AUD 0.01 | AUD 7.3 M | P/E = 1.28; JV with Nittetsu; debt extinguishment |
| CCM (CCM.AX) | +13.64 % | AUD 0.02 | AUD 7.2 M | Significant upside |
| WOA (WOA.AX) | –9.09 % | AUD 0.01 | AUD 7.2 M | Decline |
Eagle Mountain Mining’s (EM2.AX) recent restructuring—particularly the joint venture with Nittetsu Mining and the repayment of debt to Vincere—illustrates a broader trend among specialty resource firms to consolidate assets and partner strategically. While Acrux operates in a different sector, its own focus on niche transdermal platforms positions it for similar upside if it can translate product development milestones into commercial traction.
Company Profile
Acrux Limited is a specialty pharmaceutical entity headquartered in West Melbourne. The firm concentrates on transdermal drug delivery systems and holds Pooled Development Fund status. Its portfolio spans hormone therapies for women’s health, anti‑aging skin care, haircare products, and veterinary pharmaceuticals. For deeper insights into Acrux’s product pipeline and corporate strategy, visit the company’s website at www.acrux.com.au .
Prepared with an insider view of Acrux’s strategic direction and market positioning.